Besponsa (inotuzumab ozogamicin, previously CMC-544) is an approved therapy developed by Pfizer to treat adults with B-cell precursor acute lymphoblastic leukemia (ALL) whose disease has relapsed or who did not respond to standard therapy.. Our contribution to the UK spans research and development, supporting education, charitable donations and collaborations with organisations across the healthcare spectrum.. Medical information for Besponsa including therapeutic indications, usage and dosage instructions, plus benefits and possible risk factors.. The National Institute for Health and Care Excellence will reassess Pfizer’s Besponsa (inotuzumab ozogamicin) as a treatment for adults with a certain form of leukaemia.. BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The table below provides a brief overview of relevant billing and coding information for BESPONSA, presented in greater detail with the sample. The US Food and Drug Administration has approved the targeted therapy drug Besponsa (inotuzumab ozogamicin) for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that is not getting better with treatment, or came back after treatment. B-cell precursor ALL is a type of cancer in which.